Personalis Announces Launch of Public Supplying of Typical Stock | Business enterprise & Finance

MENLO PARK, Calif.–(Business WIRE)–Jan 26, 2021–

Personalis, Inc. (Nasdaq: PSNL), a leader in state-of-the-art genomics for population sequencing and cancer, these days introduced that it has commenced an underwritten public featuring of $150. million of its widespread stock. In addition, Personalis expects to grant the underwriters a 30-day option to acquire up to an added $22.5 million of popular stock on the same terms and disorders.

The giving is issue to sector disorders, and there can be no assurance as to whether or not or when the supplying may perhaps be completed or as to the precise sizing or terms of the presenting.

Morgan Stanley, BofA Securities, Citigroup and Cowen are acting as joint ebook-operating managers. BTIG is acting as co-supervisor.

A shelf registration statement relating to the shares being offered in this supplying was filed with the U.S. Securities and Trade Commission on December 30, 2020, and was declared productive on January 8, 2021. The presenting will be produced only by means of a prospectus nutritional supplement and accompanying prospectus. A preliminary prospectus nutritional supplement and accompanying prospectus relating to the presenting have been submitted with the SEC and are accessible for free on the SEC’s internet site situated at http://www.sec.gov. When obtainable, digital copies of the preliminary prospectus nutritional supplement and accompanying prospectus relating to the proposed community offering may possibly be attained from Morgan Stanley & Co. LLC, Interest: Prospectus Section, 180 Varick Road, 2 nd Flooring, New York, NY 10014 BofA Securities, Notice: Prospectus Division, NC1‐004‐03‐43, 200 North Higher education Road, 3rd ground, Charlotte, NC 28255‐0001, or by emailing dg.prospectus—[email protected] Citigroup World Markets Inc., c/o Broadridge Monetary Methods, 1155 Lengthy Island Avenue, Edgewood, NY 11717, or by phone at 1-800-831-9146 or Cowen and Corporation, LLC, c/o Broadridge Monetary Alternatives, Attention: Prospectus Office, 1155 Very long Island Avenue, Edgewood, NY 11717, phone: 1-833-297-2926.

This push launch shall not constitute an supply to offer or the solicitation of an supply to obtain, nor shall there be any sale of these securities in any state or jurisdiction in which these kinds of present, solicitation, or sale would be unlawful prior to registration or qualification beneath the securities legislation of any this sort of condition or jurisdiction.

Personalis, Inc. is a leader in population sequencing and most cancers genomics, with a aim on facts, scale, effectiveness and high quality. Personalis operates a person of the premier sequencing programs globally and is now the sole sequencing supplier to the U.S. Office of Veterans Affairs Million Veterans Software. In oncology, Personalis is transforming the enhancement of upcoming-era therapies by providing much more extensive molecular info about each individual patient’s most cancers and immune response. The Personalis ®ImmunoID Subsequent System® is created to adapt to the intricate and evolving comprehending of cancer, offering its biopharmaceutical prospects with data on all of the around 20,000 human genes, jointly with the immune program, from a single tissue or blood sample. The Personalis ®Medical Laboratory is GxP aligned as properly as CLIA’88-certified and CAP-accredited.

Ahead-Hunting Statements

This push release incorporates forward-on the lookout statements, which include statements relating to Personalis’ expectations concerning the proposed public offering. These statements are issue to substantial hazards and uncertainties and genuine results could vary materially from those people projected. Personalis cautions investors not to spot undue reliance on the ahead-searching statements contained in this release. These risks and uncertainties involve, with no limitation, hazards and uncertainties similar to market place disorders, the danger that the proposed general public featuring will not be consummated on the terms or in the amounts contemplated or if not, and the fulfillment of customary closing disorders connected to the proposed general public providing. Hazards and uncertainties relating to Personalis and its company can be observed in the “Risk Factors” sections of Personalis’ Kind 10-Q for the quarter finished September 30, 2020, filed with the SEC on November 5, 2020, the self registration statement filed with the SEC on December 30, 2020 and the preliminary prospectus nutritional supplement connected to the proposed community giving submitted with the SEC on January 26, 2021. Personalis undertakes no responsibility or obligation to update any forward-on the lookout statements contained in this launch as a final result of new information and facts, upcoming occasions or variations in Personalis’ expectations, apart from as necessary by legislation.

Get in touch with: Trader Relations Call for Personalis: 

415-202-5678Media Contact for Personalis: 

Key word: CALIFORNIA UNITED STATES NORTH The us

Industry Keyword: Exploration GENETICS Clinical TRIALS BIOTECHNOLOGY Well being PHARMACEUTICAL OTHER SCIENCE SCIENCE ONCOLOGY

Copyright Small business Wire 2021.

PUB: 01/26/2021 04:31 PM/DISC: 01/26/2021 04:31 PM

Copyright Business enterprise Wire 2021.